STELARA is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Janssen Biotech, Inc.. The primary component is Ustekinumab.
| Product ID | 57894-061_17da6982-46cb-4cc7-a05b-12c3370734d1 |
| NDC | 57894-061 |
| Product Type | Human Prescription Drug |
| Proprietary Name | STELARA |
| Generic Name | Ustekinumab |
| Dosage Form | Injection, Solution |
| Route of Administration | SUBCUTANEOUS |
| Marketing Start Date | 2009-09-25 |
| Marketing Category | BLA / BLA |
| Application Number | BLA125261 |
| Labeler Name | Janssen Biotech, Inc. |
| Substance Name | USTEKINUMAB |
| Active Ingredient Strength | 90 mg/mL |
| Pharm Classes | Interleukin-12 Antagonists [MoA],Interleukin-23 Antagonist [EPC],Interleukin-23 Antagonists [MoA],Interleukin-12 Antagonist [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
| Marketing Start Date | 2009-09-25 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA125261 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2009-09-25 |
| Marketing Category | BLA |
| Application Number | BLA125261 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2009-09-25 |
| Marketing Category | BLA |
| Application Number | BLA125261 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2009-09-25 |
| Marketing End Date | 2009-09-30 |
| Ingredient | Strength |
|---|---|
| USTEKINUMAB | 90 mg/mL |
| SPL SET ID: | c77a9664-e3bb-4023-b400-127aa53bca2b |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 57894-054 | Stelara | ustekinumab |
| 57894-060 | STELARA | ustekinumab |
| 57894-061 | STELARA | ustekinumab |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() STELARA 78932838 3791626 Live/Registered |
Johnson & Johnson 2006-07-19 |
![]() STELARA 77725780 4049691 Live/Registered |
JOHNSON & JOHNSON 2009-04-30 |